ࡱ> 5@tbjbj22 OXXY'$P,Fl7(6666666$<8R:b6E6@7--- 6-6-L-.r4T5 9(495V7074:1-:5:58Z@@-4]661-XExpression of 5HT-1A and 5HT-1B Receptor Genes in Brains of Wistar-Zagreb 5HT Rats Running title: 5HT receptors in Wistar-Zagreb 5HT rats Tatjana Bordukalo-Nikai, Gordana Mokrovi, Branimir Jernej and Lipa i in-`ain Department of Molecular Biology, Rudjer Boskovic Institute, Zagreb, Croatia ABSTRACT By selective breeding, two sublines of rats with high or low activity of platelet serotonin transporter (5HTt) have been developed (Wistar-Zagreb 5HT rats). Previous studies demonstrated significant differences between sublines in the expression of platelet 5HTt at the level of both, mRNA and protein. Analysis of brain 5HTt gene expression did not show analogous differences, although pharmacological studies showed marked alterations in brain 5HTt function, indicating differences in central 5HT homeostasis. In this study, we searched for possible changes in the expression of two central 5HT receptor subtypes: 5HT-1A and 5HT-1B, both participating in the regulation of brain 5HT transmission. Semi-quantitative RT-PCR, with three different housekeeping genes as internal standards, showed no differences in 5HT-receptor messages between sublines. Results suggest that constitutional alteration of serotonergic transmission, induced by inherited dysregulation of the 5HT transporter, did not cause measurable changes in the expression of central 5HT-1A (hippocampus) and 5HT-1B (striatum) receptors in the mentioned rat sublines. Key words: serotonin receptor, gene expression, rat brain Introduction Serotonin (5-hydroxytryptamine, 5HT) exerts its effects through at least 15 different receptors which are grouped into 7 main types. All 5HT receptor subtypes, except of 5HT-3 receptor, are members of the G-protein coupled receptor superfamily1. Serotonin-1A (5HT-1A) receptor is the most extensively studied of all 5HT receptor subtypes and has been shown to have a role in physiological functions such as cognition and emotions; they also play an important role in regulation of neuroendocrine functions and responses to stress2, as well as in neural development3. They are involved in etiopathology of certain neuropsychiatric disorders, e.g. anxiety and depression4,5, and in the mechanism of action of antidepressant drugs6. 5HT-1A receptors are expressed both, postsynaptic to 5HT neurons (in forebrain regions, hippocampus particularly) and also on the 5HT neurones at the level of the soma and dendrites in the raphe nuclei7. This heterogeneity in distribution of 5HT-1A receptors has been associated with diversity in pharmacology and signal transduction characteristics of the receptor3,8. By regulation of neuronal firing, somatodendritic 5HT-1A autoreceptors are particularly important in regulation of serotonergic neurotransmission, as demonstrated in electrophysiological and microdyalisis studies9. Postsynaptic 5HT-1A receptors seem to participate in modulating release of other neurotransmitters (acetylcholine, noradrenaline)7, contributing thus to overall transmission10. Mice with genetically inactivated 5HT-1A receptor (5HT-1A knockout mice) develop anxiety-like phenotype and increased responsiveness to stress11. Serotonin-1B receptors (5HT-1B) have been found on both, serotonergic and non-serotonergic neurons, acting as presynaptic auto- and hetero-receptors. By regulating terminal serotonin release12, they have an important role in controlling synaptic 5HT transmission. They are involved in several physiological functions, behaviors and diseases, including locomotor activity, drug abuse, migraine, anxiety states and aggressive behavior12,13. 5HT-1B knockout mice showed increased aggressiveness, increased exploratory activity14 and increased vulnerability to cocaine15. Similarly to 5HT-1A receptors, expression of 5HT-1B receptors is also influenced by antidepressant drugs16. By selective breeding for the extreme values of platelet serotonin level (PSL), we have previously developed two sublines of rats differing markedly in this trait17. Further studies indicated platelet serotonin transporter (5HTt) as the protein substrate being under genetic pressure and underlying the observed differences in PSL between sublines18,19. This allowed more specific selective breeding for the extreme values of platelet serotonin uptake (PSU) velocity, which finally resulted in development of two rat sublines with high and low 5HTt velocity, referred as Wistar-Zagreb 5HT rats. It seems that, besides in platelets, selection process affected serotonin homeostasis in general, including the brain20,21. Indeed, pharmacological challenge with citalopram (SSRI antidepressant) resulted in markedly different response of extracellular 5HT level in ventral hippocampi between 5HT-sublines21, behavioral studies showed differences in learning ability, motor functions and anxiety-like behaviors22, 23, and there is an evidence that these sublines differ in alcohol intake and preference24. Detailed characterisation of high-5HT and low-5HT animals at the neurochemical and molecular genetic levels are in course. Although studies on the expression of neuronal 5HTt gene in brain cortex did not show significant differences between the sublines25, observed behavioral/functional differences strongly indicate hyper- and hypo-serotonergic neurotransmission in brains of high-5HT and low-5HT subline, respectively, making warranted studies of possible adaptational changes in neuronal 5HT receptors. This study was aimed at the mRNA encoding the two 5HT receptor subtypes, 5HT-1A and 5HT-1B in hippocampus and striatum, respective regions of their abundant expression. Materials and Methods Studies were performed on sublines of Wistar-Zagreb 5HT rats, developed as described previously25. Shortly, at the age of 5-6 weeks, PSL and PSU were determined in offspring of each generation and the males and females displaying the extreme values of PSU were mated to start a new generation of the high-5HT and low-5HT sublines, respectively. In this study females from 15th breeding generation, aged about 12 months were used (N = 8 per group). They were housed three per cage with free access to commercial rat chow and tap water. All experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals. PSL and PSU were measured in samples of platelet-rich plasma (PRP) obtained from 1 mL of venous blood, according to reported procedure26,27. Tissue (hippocampi and striata) were quickly excised from the fresh brains, after decapitation of the animal, and rapidly frozen in the liquid nitrogen. RNA was isolated from brain tissue by standard acid guanidinium-phenol-chloroform extraction28. Isolated RNA was further purified with RNeasy micro kit (Qiagen, Germany), which included removal of genomic DNA. 1 (g of total RNA was used for synthesis of single-stranded cDNA. Reverse transcription (RT) mixture contained following constituents: 2 (L of oligo d(T)16 primers, 1 RT buffer, 1 mM deoxynucleotide triphosphate, 5 mM MgCl2, 20 U of RNasIn and 15 U of AMV reverse transcriptase (Promega, USA). PCR was performed in a total volume of 20 (L, which contained 1 (L of RT mixture, 1 PCR buffer, 0.2 mM dNTP and 0.6 U Taq DNA polymerase (Applied Biosistems, USA). Final concentrations of MgCl2 and specific oligonucleotide primers, as well as sequences of oligonucleotide primers25,29,30 and expected RT-PCR product sizes are given in Table 1. All oligonucleotide primers were custom synthesized by Life Technologies (Vienna, Austria). The PCR conditions were as follows: 30'' at 94C, 30'' at 60C and 45'' at 72C. To determine the appropriate number of PCR cycles, at which linear phase is maintained, for each primer set PCRs at different number of cycles, and with given amount of cDNA (1 (L), were run. Optimal number of cycles for each set of primers is also given in Table 1. Three typical housekeeping genes (GAPDH, (-actin, cyclophylin B) were used as internal controls. Expression of 5HT-1A receptor gene was studied in hippocampus, and expression of 5HT-1B receptor gene in striatum. 10 (L of PCR products were separated on a 1.5% agarose gel with TAE buffer, containing 0.1% ethidium bromide. Electrophoresis of PCR products from each reaction revealed single band of the expected product size (see Table 1). Gels were scanned on the Image Master VDS apparatus. Digital images were densitometrically analysed using Image MasterTM software (Pharmacia Biotech, USA). The amount of 5HTt mRNA was expressed as a ratio between the amount of PCR product of 5HTt cDNA and the corresponding amount of each of the control cDNAs. Normalized values were analysed for the presence of outliers and checked for differences using t-test, with the level of significance set at 0.05. Results By the use of described protocols the 5HT-1A and 5HT-1B mRNA levels were compared in brains of animals from high-5HT and low-5HT sublines of Wistar-Zagreb 5HT rats. The same groups of animals demonstrated approximately twofold difference in their platelet 5HT transporter velocity. 5HT-receptor mRNA from brains of two high-5HT and two low-5HT animals were analysed in the same experiment simultaneously with three corresponding reference genes (GAPDH, (-actin, cyclophylin B), used as internal standards for normalizing 5HT-receptor messages. The same paradigm was followed for 5HT-1A and 5HT-1B cDNA. PCR for 5HT-1A receptor was performed at 28 cycles, and for 5HT-1B receptor at 32 cycles. For details about PCR conditions, see Table 1. Optimization of the number of PCR cycles for the reference genes was determined previously25. Figure 1 shows the results of 5HT-1A gene expression in hippocampi of Wistar-Zagreb 5HT sublines. Ratio of 5HT receptor signal/reference gene signals were calculated for all three referent genes and than the level of 5HT-1A expression in low-5HT subline is given as percent of the 5HT-1A expression in high-5HT subline (designated as 100%). No difference in the expression of 5HT-1A gene in the hippocampus was observed between sublines, regardless of the housekeeping gene used to normalize receptor signal. Analogous analysis of 5HT-1B gene expression in striata of high- and low-5HT sublines is shown in Figure 2. Again, no differences between the sublines were found. Discussion By using the originally developed method for the ex vivo monitoring of PSU kinetics in the individual rat27, the directed genetical selection of animals for the extreme values of PSU resulted in development of two sublines of Wistar-Zagreb 5HT rats31. They demonstrated pronounced differences in the velocity of platelet 5HTt, which is encoded by the same gene as its central counterpart. Further neuropharmacological and behavioural studies suggested that the selection process had functional impact also on the brain serotonergic homeostasis20,21,22,23. In that case sublines of Wistar-Zagreb 5HT rats might represent a useful model of animals with constitutionally up- and down-regulated 5HT neurotransmission, which could find applications in different fields of 5HT-related research. By our knowledge, no similar model has been described. It should be stressed that 5HT-rats are generated under physiological conditions (simple breeding selection), what make this rat model different from most other currently available animal models, such as knockout-mice or pharmacological models. In contrast to knockout animals, where change in 5HTt activity is unidirectional (gene function completely abrogated), model of Wistar-Zagreb 5HT rats includes bidirectional changes, i.e. up- and down-regulation of 5HTt transmission in 5HT-sublines31. Although molecular genetic studies showed clear differences in platelet 5HTt mRNA and protein levels between the sublines18,19, studies on the expression of 5HT-related genes in brain cortex, notably expression of 5HTt gene, did not demonstrate analogous differences25. Under physiological conditions, also the activity of 5HT transporters in brain cortex seems to be similar between 5HT-sublines (unpublished results). However, constitutively altered brain functioning, as demonstrated by differences in brain 5HT turnover (unpublished results), in extrasynaptic 5HT concentration21, as well as in response to pharmacological challenge21 between sublines strongly suggest differentially regulated brain 5HT neurotransmission, possibly involving 5HT receptors. Thus, this study was aimed to compare the expression of 5HT-1A and 1B receptors, as important regulators of 5HT nerotransmission12,32, in brains of Wistar-Zagreb 5HT rats. Expression of both receptor genes was studied in regions where they are abundantly expressed - 5HT-1A receptor in hippocampus, and 5HT-1B receptor in striatum. In order to obtain reliable results, expression of target genes was related to three different reference genes in parallel. We have shown that messages for both 5HT-receptor genes under study are quite similar between the sublines, notwithstanding reference gene used to normalise expression signals. Expression of 5HT-1A and 5HT-1B receptor genes has been explored in mice with genetically inactivated 5HTt gene. Studies on 5HTt knockout mice demonstrated region-specific changes in the expression of 5HT-1A and 5HT-1B receptor mRNAs33,34. Thus, Fabre et al. (2001) have shown marked reduction in 5HT-1A mRNA levels in raphe region, in contrast to higher level of this transcript measured in hippocampus33, with the expression of 5HT-1B receptor gene not differing between knockout and wild type mice33. Similarly, Li et al. (2000) have found significant decrease of 5HT-1A mRNA level only in dorsal raphe area, while mRNA levels in hypothalamus remained unchanged when compared to wild type animals34. Electrophysiological studies on 5HTt knockout mice reported regional differences (raphe vs hippocampus) in pharmacologically induced 5HT-1A receptor desensitization35. In addition, chronic treatment of rats with selective 5HT reuptake inhibitor, fluoxetine, resulted in region-specific adaptation of 5HT-1A and 5HT-1B receptor, at both mRNA36 and protein function level36,37. All these findings suggest that adaptational changes in 5HT-1A and -1B receptors could have been expected also in our animal model. The observed absence of differences in their expression between sublines might be due to several reasons. For example, there could be changes only at the protein level, without altering mRNA expression. Similarly, Fabre et al. (2000) found significant decrease in 5HT-1B receptor labelling in 5HTt knockout mice, while levels of 5HT-1B mRNA revealed no differences. In this case, post-transcriptional steps accounted for the mentioned down-regulation of 5HT-1B receptors33. Another possible explanation of our findings may be that marked alterations in brain neurochemistry (i.e.cellular/extracellular 5HT levels) are needed to provoke measurable changes in adaptation of receptors. Thus, in contrast to our model, 5HTt knockout mice showed marked reductions in 5HT concentrations in various brain regions, while levels in heterozygous mice remained unchanged38. It must be emphasized that the present study was aimed at postsynaptic 5HT receptors. In view of the literature data, there is possibility that measured transcripts differ between raphe area in our sublines, so study on the expression of 5HT-1A and 5HT-1B autoreceptors in raphe nuclei should also be considered, as well as studies at the protein level (i.e. Western blot and/or receptor binding studies). Finally, there is also a possibility that differences between sublines in the expression of 5HT receptors important for the regulation of brain neurotransmission, became evident only on pharmacological or behavioural/stressful challenge. Literature data repeatedly show influence of stress on the expression of 5HT-1A receptors39,40,41, at both mRNA and protein level, as well as on the expression of 5HT-1B receptors42,43. Similar studies on Wistar-Zagreb 5HT rats could possibly contribute to understanding the role of 5HT neurotransmission in mechanisms of drug action and/or stress mechanisms. Acknowledgements. The results from this study are published within the scope of the project "Serotonergic neurotransmission: genes, proteins and behavior", supported by Croatian Ministry of Science, Education and Sport. References 1. LANFUMEY L, HAMON M, Nucl Med Biol, 27 (2000) 429. 2. HENSLER JG, Life Sci, 72 (2003) 1665. 3. PUCADYIL TJ, KALIPATNAPU S, CHATTOPADHYAY A, Cell Mol Neurobiol, 25 (2005) 553. 4. GROSS C, ZHUANG X, STARK K, RAMBOZ S, OOSTING R, KIRBY L, SANTARELLI L, BECK S, HEN R, Nature, 416 (2002) 396. 5. NEUMAISTER A, YOUNG T, STASTNY J, Psychopharmacol, 174 (2004) 512. 6. CELADA P, PUIG MV, AMARGOS-BOSCH M, ADELL A, ARTIGAS F, J Psychiat Neurosci, 29 (2004) 252. 7. BARNES NM, SHARP T, Neuropharmacol, 38 (1999) 1083. 8. RAYMOND JR, MUKHIN YV, GELASCO A, TURNER J, COLLINSWORTH G, GETTYS TW, GREWAL JS, GARNOVSKAYA MN, Pharmacol Ther, 92 (2001) 179. 9. SHARP T, HJORTH S, J Neurosci Meth, 34 (1990) 83. 10. EL MANSARI M, BLIER P, Rev Psychiat Neurosci, 30 (2005) 268. 11. TOTH M, Eur J Pharmacol, 463 (2003) 177. 12. OLIVIER B, VAN OORSCHOT R, Eur J Pharmacol, 526 (2005) 207. 13. SARI Y, Neurosci Biobehav Rev, 28 (2004) 565. 14. ASE AR, READER TA, HEN R, RIAD M, DESCARRIES L, J Neurochem, 78 (2001) 619. 15. ROCHA BA, SCEARCE-LEVIE K, LUCAS JJ, HIROI N, CASTANON N, CRABBE JC, NESTLER EJ, HEN R, Nature, 393 (1998) 175. 16. CLARK MS, NEUMAIER JF, Psychopharmacol Bull, 35 (2001) 170. 17. JERNEJ B, CICIN-SAIN L, Psychiat Res, 32 (1990) 67. 18. JERNEJ B, HRANILOVIC D, CICIN-SAIN L, Neurochem Int, 33 (1999) 519. 19. HRANILOVIC D, HERAK-KRAMBERGER CM, CICIN-SAIN L, SABOLIC I, JERNEJ B, Life Sci, 69 (2001) 59. 20. HRANILOVIC D, CICIN-SAIN L, BORDUKALO T, JERNEJ B, Am J Med Gen, 114 (2002) 883. 21. ROMERO L, JERNEJ B, BEL N, CICIN-SAIN L, CORTES R, ARTIGAS F, Synapse, 28 (1998) 313. 22. HRANILOVIC D, CICIN-SAIN L, BORDUKALO-NIKSIC T, JERNEJ B, Behav Brain Res, 165 (2005) 271. 23. QUEVEDO G, MOSCOSO O, PRADO-MORENO A, CICIN-SAIN L, JERNEJ B, DELGADO-GARCIA JM, Behavioral and molecular studies in rats over-expressing and under-expressing serotonin transporter. In: COST B10 Meeting (2002). 24. CICIN-SAIN L, BORDUKALO-NIKSIC T, JERNEJ B, Wistar-Zagreb 5HT rat: a new animal model of alcoholism. In: J Alcohol Relat Addict, suppl. 40 (2004) 92. 25. BORDUKALO-NIKSIC T, CICIN-SAIN L, JERNEJ B, Neurosci Lett, 369 (2004) 44. 26. JERNEJ B, CICIN-SAIN L, ISKRIC S, Life Sci, 43 (1988) 1663. 27. JERNEJ B, FROEBE A, HRANILOVIC D, CICIN-SAIN L, Neurosci Res Commun, 24 (1999), 163. 28. CHOMCZYNSKI S, SACCHI N, Anal Biochem, 162 (1987) 156. 29. KULIKOV AV, NAUMENKO VS, VORONOVA IP, TIKHONOVA MA, POPOVA NK, J Neurosci Meth, 141 (2005) 97. 30. LIU XY, WU SX, WANG YY, WANG W, ZHOU L, LI YQ, Neurosci Lett, 375 (2005) 42. 31. CICIN-SAIN L, FROEBE A, BORDUKALO-NIKSIC T, JERNEJ B, Life Sci, 77 (2005) 452. 32. ALBERT PR, LEMONDE S, Neuroscientist, 10 (2004) 575. 33. FABRE V, BEAUFOUR C, EVRARD A, RIOUX A, HANOUN N, LESCH KP, MURPHY DL, LANFUMEY L, HAMON M, MARTRES MP, Eur J Neurosci, 12 (2000) 2299. 34. LI Q, WICHEMS C, HEILS A, LESCH KP, MURPHY DL, J Neurosci, 20 (2000) 7888. 35. MANNOURY LA COUR C, BONI C, HANOUN N, LESCH KP, HAMON M, LANFUMEY L, J Neurosci, 21 (2001) 2178. 36. LE POUL E, BONI C., HANOUN N, LAPORTE AM, LAARIS N, CHAUVEAU J, HAMON M, LANFUMEY L, Neuropharmacol, 39 (2000) 110. 37. NEWMAN ME, SHALOM G, RAN A, GUR E, VAN DE KAR LD, Eur J Pharmacol, 486 (2004) 25. 38. BENGEL D, MURPHY DL, ANDREWS AM, WICHEMS CH, FELTNER D, HEILS A, MSSNER R, WESTPHAL H, LESCH KP, Mol Pharmacol, 53 (1998) 649. 39. LOPEZ JF, CHALMERS DT, LITTLE KY, WATSON SJ, Biol Psychiat, 43 (1998) 547. 40. LOPEZ JF, LIBERZON I, VASQUEZ DM, YOUNG EA, WATSON SJ, Biol Psychiat, 45 (1999) 934. 41. BRIONES-ARANDA A, ROCHA L, PICAZO O, Prog Neur Psychopharmacol Biol Psychiat, 29 (2005) 275. 42. NEUMAIER JF, EDWARDS E., PLOTSKY PM, Biol Psychiat., 51 (2002) 902. 43. KAIYALA KJ, VINCOW ES, SEXTON TJ, NEUMAIER JF, Pharm Biochem Behav, 75 (2003) 769 Corresponding author: L. i in-`ain, Laboratory of Neurochemistry and Molecular Neurobiology, Molecular Biology Department, Rudjer Boskovic Institute, Bijenicka 54, HR-10000 Zagreb, Croatia e-mail: cicinsai@rudjer.irb.hr Tatjana Bordukalo-Nikai, Gordana Mokrovi, Branimir Jernej, Lipa i in-`ain EKSPRESIJA GENA ZA 5HT-1A I 5-HT-1B RECEPTORE U MOZGU WISTAR-ZAGREB 5HT `TAKORA SA}ETAK. Usmjerenom selekcijom prema ekstremnim vrijednostima brzine trombocitnog serotoninskog prijenosnika (5HTt) razvijene su dvije sublinije atakora s visokom odnosno niskom vrijednoau toga parametra, nazvane  Wistar-Zagreb 5HT atakori . Prethodna istra~ivanja pokazala su zna ajne razlike izmeu sublinija u ekspresiji trombocitnog 5HTt, na razini i mRNA i proteina. U mozgu nisu pokazane analogne razlike, ali farmakoloake studije pokazuju jasne funkcionalne promjene 5HT prijenosnika, te jasno upuuju na postojanje razlika u centralnoj 5HT homeostazi izmeu sublinija. U ovom radu je istra~ena ekspresija gena za dva podtipa 5HT receptora: 5HT-1A receptor u hipokampusu i 5HT-1B receptor u st. / 9 56IL"#df&(su [\gl4UWVX&0uhCmHsHhCCJmHsH hp)CJ hC5CJ hCCJH*hC56CJ hp)6 hC6hC hC7CJ hC6CJ hCCJE  ) * + , . / 8 9 $a$$rh U !"$(*M+N+V+q,.:1;1<1d$da$$da$$a$uw! "%"####$$,$.$r$s$$$$${%|%%%r's''''' ((((())*M+--..:1;1x1111A2C2h3s366777758䲻 hC6CJhC5CJmHsH hCCJH* jbhCCJ hCCJhCCJH*mHsH jmhCCJmHsHhCCJH*mHsHhCCJmHsHhCmHsHhCH*mHsH:<1G169;BDEHHHHHHHWWWWWWWWWW X"XTYY$a$$da$58B888899:::I;<<====>>??]?_? @@*@/@BBDDDDEEFFKGPGHH^HHHHHIOOO QQSWSWWWXYYY8ZZV`ruuu槶 hCCJU hC5CJhChCmHsHhC6CJmHsHhC5CJmHsH hC6CJ hCCJH* hCCJhCCJmHsHh`CJmHsHBYYYY6Z8ZZZZ`_uuuuuuxxxzzzzzzz $$Ifa$$a$$|`|a$$h^ha$$a$rijatumu 5HT-sublinija. Metodom semi-kvantitativnog RT-PCR, provedenog uz tri razli ita referentna gena, nisu pokazane razlike u ekspresiji navedenih receptorskih gena. Rezultati upuuju da konstitucijske promjene serotonergi ne neurotransmisije potaknute poja anom ili smanjenom aktivnoau serotoninskog prijenosnika nisu dovele do promjena u ekspresiji postsinapti kih 5HT-1A, odnosno 5HT-1B receptora kod Wistar-Zagreb 5HT atakora u fizioloakim uvjetima. FIGURE HEADINGS Figure 1. 5HT-1A expression in hippocampi of animals from high-5HT and low-5HT sublines. 5HT-1A mRNA levels are expressed as ratio in respect to different control genes (GAPDH, (-actin and cyclophylin) and the level of expression of 5HT-1A in low-5HT subline is given as percent of expression in high-5HT subline (=100%). Each column represents mean( SD of 8 animals. No significant differences were detected. Figure 2. 5HT-1B expression in striata of animals from high-5HT and low-5HT sublines. For details see Figure 1. Each column represents mean( SD of 8 animals. No significant differences were detected. TABLE 1 PCR CONDITIONS AND PRIMER SEQUENCES target mRNAMgCl2 concentration (mM)primer concentration ((M)optimal number of PCR cyclesprimer sequenceexpected product size (bp)5HT-1A1.00.8285' CCCCCCAAGAAGAGCCTGAA 3' 5' GGCAGCCAGCAGAGGATGAA 3'3365HT-1B1.50.8325' CTGCTAAAAGAACTCCCAAAA 3' 5' TTGGGTGTCTGTTTCAAAATC 3'262GAPDH2.00.4245' AGAACATCATCCCTGCATCC 3' 5' TCCACCACCCTGTTGCTGTA 3'367b-actin2.00.4265' GAAACTACCTTCAACTCCATC 3' 5' CTAGAAGCATTTGCGGTGGACGAT 3'303cyclophylin B2.00.4265' CCATCGTGTCATCAAGGACTTCAT 3' 5' TTGCCGTCTAGCCAGGAGGTCT 3'216     PAGE 4 PAGE 3 uuuu w"wxxzxxxx zzzzzz{{Z{\{}} "$&*,0268<>JLN{{{{qkq`hC0JmHnHu hC0JjhC0JUh+jh+U hCCJhCCJOJQJmHsH jmhCCJmHsHhCCJH*mHsHhC5CJmHsHhC jhC6CJmHsH jbhC6CJmHsHhC56CJmHsHhC6CJmHsHhCCJmHsH%z.{b{{{{{=kd$$Iflֈ|$ x4|)81TTTH04 la $$Ifa${| |||P||| $$Ifa$|||||||F===== $$Ifa$kd$$Iflֈ|$ x4|)81TTTH04 la|$},}.}:}B}J}=kd$$Iflֈ|$ x4|)81TTTH04 la $$Ifa$J}P}}}}}};kd$$IflJֈ|$ x4|)81TTTH04 la $$Ifa$}}}}$~b~j~ $$Ifa$j~l~~~~~~F===== $$Ifa$kd$$Iflֈ|$ x4|)81TTTH04 la~ "$(=;9;kd$$Iflֈ|$ x4|)81TTTH04 la $$Ifa$(*.046:<RTVlnprth]h&`#$NPRVXdfhjlprt hCCJh+h*bm0JmHnHuhC hC0JjhC0JU $1h. A!"#$% '1h0A .!"#$% $$If!vh5T5T5T55H5#vT#v#vH#v:V l0,5T55H5/  4a$$If!vh5T5T5T55H5#vT#v#vH#v:V l0,5T55H5/ 4a$$If!vh5T5T5T55H5#vT#v#vH#v:V l0,5T55H5/ 4a$$If!vh5T5T5T55H5#vT#v#vH#v:V lJ0,5T55H5/ 4a$$If!vh5T5T5T55H5#vT#v#vH#v:V l0,5T55H5/ 4a$$If!vh5T5T5T55H5#vT#v#vH#v:V l0,5T55H5/  4a8@8 Normal_HmH sH tHJ@J Heading 2$$@&a$CJmHsHuF@F Heading 5$@&6CJmHsHuDA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k(No List 2B@2 Body TextCJ4 @4 Footer  p#.)@. Page Number<P@"< Body Text 2$a$CJJQ@2J Body Text 3$a$6CJmHsHukWY&ST)*+,./89h U!M"N"V"q#%:(;(<(G(-029;<???????NNNNNNNNNN O OOOOOOPPgPhPiPRTTTUUUVVViWjWkWsWWWWWWWX X!X(X,X0X3XNXiXmXnXuXyX}XXXXXXXXXXXYY YYYYY8YWY[Y\YjYnYrYuYYYYYYYYYYYYYYYYYY0000000000000000000000000000000000000p00000000000000000000p00000000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 0 0 0 0 00 0 0 00@0@0@0@0@0@0@0@0@0@04 &&&&&&&&&)u58uNt157@J<1Yz{||J}}j~~(t2468ABCDEFGHIr3  ")!t!`ZWaZ XbZWcZLWdZ WeZLX!lDTPTPY((qDZPZPYh*urn:schemas-microsoft-com:office:smarttagsCity0http://www.5iamas-microsoft-com:office:smarttagsV*urn:schemas-microsoft-com:office:smarttagsplacehttp://www.5iantlavalamp.com/_*urn:schemas-microsoft-com:office:smarttagscountry-regionhttp://www.5iantlavalamp.com/ &0wy%'!./su|}rs M"5//112I2;;???^??????@@@ @@'@.@/@1@8@;@R@Z@[@]@_@j@n@{@@@@@@@@@@@A%A2A9A=ALAcAiAmAqAvA}AAAAAAAAAAA BBBBBB)B5B9B?B@BBBDBJBOBZB[B]B_BhBiBmBBBBBBBBBBBBBBBBCC C CC=CECICLCOCXCxCCCCCCCCCCCCD DDDD D$D,D0D6D7D9D;DBDCDEDvD~DDDDDDDDDDDDDE EEEEE2EHLHTHUHYHzHHHHHHHHIJ JJJJ*J=J@JWJJKLMNNNN O OOP!P"P&P'P)P;PDPGPLP_PfPiPpPrP|P}PPPPPPPPPPPPPPPPPPPPPPPPPQQ Q QQQQQ&Q,Q5Q7Q>QRQYQ\QeQfQrQsQ{Q|Q~QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQRR R RRRRR'R(R-R.R:R;RCRHRTRVRXRYR^R_RfRgRiRjRtRuR|RRRRRRRRRRRRRRRRRRRRRRRRRRRRRSSSS$S.S3SSESKSYSbSlSmSoStS}S~SSSSSSSSSSSSSSSSSSSSSSSSSSSSS T TTT%T&T/T0T3T4T=T>THTITVTWTcTdThTiToTsT{T~TTTTTTTTTTTTTTTTTUUUUUUbVdVVV,W.WiWkWWWWWWW X!XmXnXXXY Y[Y\YYYYYYYYYYYYYYYYYYYYJ L ily!!L"$$j*s*--..111I233,7/7:=L===??'@L@R@@A]AcAAAABBBBB'C.CiCCClDDDDD+E2EEEBFIF HiHpHHHJPJWJNNNN O OOOOiPqPrP[QQQR R>SS0T3TTUUVVhWkWrWsWWWWWWWWWWWXXX!X'X(X+X,X/X0X2X3XMXNXhXiXlXnXtXuXxXyX|X}XXXXXXXXXXXXXXXXXXXYYY YYYYYYYYY7Y8YVYWYZY\YiYjYmYnYqYrYtYuYYYYYYYYYYYYYYYYYYYY3333333333333333333333333333333333333333YYYYYYYYYYYYYYLipa i in-`ainLipa i in-`ainLipa i in-`ainLipa i in-`ainLipa i in-`ainLipa i in-`ainLipa i in-`ainLipa i in-`ainLipa i in-`ainInstitutw?'+' bqK +[p hh^h`o(hH. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH. hh^h`OJQJo( hh^h`OJQJo(^`o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.w?'+[+'bqKCd<`*bm+p)CzWWWWWWX X!X(X,X0X3XiXmXnXuXyX}XXXXXXXXXYY YYYYYWY[Y\YjYnYrYuYYYYYYYYYYYW@@NR&SY@X`rUnknownGz Times New Roman5Symbol3& z Arial"1skfd TL-d TL-!4dYYH?` INTRODUCTIONInstitutInstitut    Oh+'0   < H T `lt| INTRODUCTIONoNTR InstitutIONnstnstNormalt InstitutION15tMicrosoft Word 10.0@2j&@Rr@r@\d TL՜.+,0 hp  RuerC-YA  INTRODUCTION Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKMNOPQRSUVWXYZ[\]^_`abcdefghijklmnopqstuvwxy{|}~Root Entry F#9Data L1TableT ;WordDocumentOSummaryInformation(rDocumentSummaryInformation8zCompObjj  FMicrosoft Word Document MSWordDocWord.Document.89q